EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Piloting New Medications for Borderline Personality Disorder: The Use of Artificial Intelligence in Psychopharmacological Research

Carlo Lazzari, Marco Rabottini

Psychopharmacology Bulletin · 2026-10-29 · 56 (4) · 26-40

DOI: 10.64719/pb.21597 ↗
AbstractBibliografische Angaben

Abstract

Background Borderline Personality Disorder (BPD) lacks approved pharmacological treatments despite a high symptom burden. Artificial intelligence (AI) offers new opportunities to accelerate drug discovery and model therapeutic effects. Objective This study will outline an AI-enabled framework for identifying and modelling a novel pharmacological agent for BPD, designed to meet five therapeutic goals: (1) reduce depression without increasing impulsivity and suicidality, (2) reduce suicidality without sedation, (3) limit side effects and weight gain, (4) reduce polypharmacy, and (5) provide combined antidepressant, anti-suicidal, mood-stabilising, and antipsychotic effects. Methods Three AI-driven approaches will be piloted: (1) deep-learning-based compound generation, (2) natural-language-processing (NLP) evidence synthesis, and (3) predictive modelling of symptom trajectories. These methods will be used to design and characterise a hypothetical multimodal compound, BPD-AI-01, including its predicted 3D molecular structure and receptor binding profile. All analyses will use publicly available data and in silico simulations. Results AI-guided modelling will generate BPD-AI-01, a candidate molecule predicted to act as a partial agonist at 5-HT1A receptors, a modulator at NMDA-associated sites, and a weak antagonist at 5-HT2A/D2 receptors, with low affinity for histaminergic and muscarinic receptors. Its 3D structure will be optimised to balance CNS penetration with reduced metabolic burden. Simulated trajectories will suggest potential antidepressant, anti-suicidal, mood-stabilising, and antipsychotic-like effects without marked sedation or weight gain. Conclusions AI-enabled pharmacological research may support the design of next-generation medications for BPD that address multiple symptom domains within a single molecule. Empirical validation will be required before any clinical application.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →